Monday, December 23, 2013

The Motley Fool: Bayer Looks to Nuke Cancer

Cancer patients have seen a wide range of new therapies hit the market in the last few years. From Seattle Genetics antibody drug conjugate approach to immunotherapies from Bristol-Myers, to advanced hormone therapies from Johnson & Johnson (NYSE: JNJ  ) and Medivation (NASDAQ: MDVN  ) . Overall, investors, companies, and patients have seen some major advances in the oncology space. Now Bayer (NASDAQOTH: BAYRY  ) is stepping up to take full control over a potential new blockbuster in prostate cancer, and a new way of attacking cancer altogether.

Continue reading here:
Bayer Looks to Nuke Cancer

No comments: